Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial
Outcomes in the Japan subgroup were broadly similar to those of the global population, supporting the clinical benefit of capivasertib-fulvestrant in treating HR-positive/HER2-negative advanced breast cancer that has progressed on, or after, an endocrine-based regimen.
Authors
- Eriko Tokunaga (ORCID: https://orcid.org/0000-0002-1640-5315)
- Tetsuhiko Taira (ORCID: https://orcid.org/0000-0002-3091-8168)
- Gaia Schiavon (ORCID: https://orcid.org/0000-0001-9059-8971)
- Sacha J. Howell (ORCID: https://orcid.org/0000-0001-8141-6515)
- Toshiro Mizuno (ORCID: https://orcid.org/0000-0002-3922-8251)
- Tatsuya Toyama (ORCID: https://orcid.org/0000-0003-4713-7795)
- Mitsuya Itoh
- Hiroji Iwata
- Seigo Nakamura (ORCID: https://orcid.org/0000-0001-6597-9107)
- Rikiya Nakamura (ORCID: https://orcid.org/0000-0002-4349-9046)
- Masakazu Toi (ORCID: https://orcid.org/0000-0003-1488-9958)
- Tomoko Sambe
- Yasuhiro Yanagita
- T. Ozaki
- Akihiko Osaki
Institutions
- AstraZeneca (United Kingdom) (GB)
- Tokyo Metropolitan Komagome Hospital (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Nagoya City University Hospital (JP)
- Chiba Cancer Center (JP)
- National Sagamihara Hospital (JP)
- Mie University Hospital (JP)
- AstraZeneca (Japan) (JP)
- Gunma Prefectural Cardiovascular Center (JP)
- Saitama International Medical Center (JP)
- Aichi Cancer Center (JP)
- The Christie NHS Foundation Trust (GB)
- SHOWA Medical University Hospital (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1007/s12282-024-01640-z
- Citations
- 8
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- AstraZeneca
- Astex Pharmaceuticals